En studie for å undersøke bruken av VH3810109 med eller uten Fostemsavir (FTR) for å redusere størrelsen og aktiviteten til det virale reservoaret hos mennesker som lever med HIV (ENTRANCE)
En utforskende fase 1B, multisenter, randomisert, åpen etikettstudie for å undersøke virkningen av administrering av intravenøs VH3810109 med eller uten oral fostemsavir i kombinasjon med integraseinhibitorbasert antiretroviral terapi på det virale reservoaret hos voksne som lever med HIV-1
This study investigates the use of VH3810109 with or without FTR to reduce the size and activity of the HIV viral reservoir in two sub-populations of people living with HIV: treatment-naïve adults (Population 1) and treatment-experienced adults currently taking a standard of care (SOC) integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) regimen (Population 2). The study is designed to include the following phases: Randomized Intervention Phase (Step 1), Analytical Treatment Interruption (ATI) Phase (Step 2), and Follow-up Phase (Step 3).
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
Brussels, Belgia, 1000
- GSK Investigational Site
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, Belgia, 9000
- GSK Investigational Site
-
-
-
-
Capital Region
-
Hvidovre, Capital Region, Danmark, 2650
- GSK Investigational Site
-
-
Central Jutland
-
Aarhus N, Central Jutland, Danmark, 8200
- GSK Investigational Site
-
-
-
-
California
-
Bakersfield, California, Forente stater, 93309
- GSK Investigational Site
-
San Diego, California, Forente stater, 92103
- GSK Investigational Site
-
-
Florida
-
Ft. Pierce, Florida, Forente stater, 34982-7148
- GSK Investigational Site
-
Orlando, Florida, Forente stater, 32803-1851
- GSK Investigational Site
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- GSK Investigational Site
-
-
Missouri
-
Kansas City, Missouri, Forente stater, 64111
- GSK Investigational Site
-
St Louis, Missouri, Forente stater, 63110
- GSK Investigational Site
-
-
New York
-
New York, New York, Forente stater, 10032
- GSK Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45267
- GSK Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- GSK Investigational Site
-
Pittsburgh, Pennsylvania, Forente stater, 15213
- GSK Investigational Site
-
-
Texas
-
Dallas, Texas, Forente stater, 75246-2004
- GSK Investigational Site
-
Dallas, Texas, Forente stater, 75208-4599
- GSK Investigational Site
-
-
-
-
-
Rotterdam, Nederland, 3015 GD
- GSK Investigational Site
-
-
-
-
-
Barcelona, Spania, 08036
- GSK Investigational Site
-
Barcelona, Spania, 08035
- GSK Investigational Site
-
Barcelona, Spania, 08003
- GSK Investigational Site
-
Barcelona, Spania, 8907
- GSK Investigational Site
-
Barcelona, Spania, 08026
- GSK Investigational Site
-
Barcelona, Spania, 08916
- GSK Investigational Site
-
Córdoba, Spania, 14004
- GSK Investigational Site
-
La Laguna Santa Cruz, Spania, 38320
- GSK Investigational Site
-
Madrid, Spania, 28041
- GSK Investigational Site
-
Madrid, Spania, 28040
- GSK Investigational Site
-
Madrid, Spania, 28046
- GSK Investigational Site
-
Madrid, Spania, 28034
- GSK Investigational Site
-
Madrid, Spania, 28031
- GSK Investigational Site
-
Madrid, Spania, 28020
- GSK Investigational Site
-
Palma de Mallorca, Spania, 07120
- GSK Investigational Site
-
Palma de Mallorca, Spania, 7198
- GSK Investigational Site
-
Seville, Spania, 41013
- GSK Investigational Site
-
Valencia, Spania, 46026
- GSK Investigational Site
-
Valencia, Spania, 46014
- GSK Investigational Site
-
-
Madrid
-
Pozuelo de Alarcón, Madrid, Spania, 28224
- GSK Investigational Site
-
-
-
-
-
London, Storbritannia, SE1 7EH
- GSK Investigational Site
-
London, Storbritannia, NW3 2QG
- GSK Investigational Site
-
London, Storbritannia, W2 1NY
- GSK Investigational Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
AGE
• Age between 18 years and 70 years old at the time of obtaining informed consent.
SEX AND GENDER • Persons of any sex or gender are eligible. Note: Participants of childbearing potential (POCBP) are eligible to participate if not pregnant, not lactating, and agreeing to adhere to study requirements for use of contraception and pregnancy avoidance.
PARTICIPANT KEY CHARACTERISTICS • Participant has a documented diagnosis of HIV-1 infection. Note: Participants in Population 1 must have a documented positive HIV antibody result available for Screening.
Population 1 only:
- Plasma HIV-1 RNA >=2000 copies/milliliter (c/mL) at Screening.
- CD4+ T cell count >=300 cells/microliter (μL) at Screening.
- Antiretroviral treatment naïve, defined as no exposure to ART after a diagnosis of HIV-1 infection, prior to enrollment.
Population 2 only:
- Participant is stably virologically suppressed (plasma HIV-1 RNA <50 c/mL).
- Documented evidence of uninterrupted treatment with oral non-boosted INSTI-based ART for at least 6 months prior to Screening, as well as uninterrupted treatment with ART (any guideline-recommended oral regimen) for at least 24 months prior to Screening.
- CD4+ T cell count >=450 cells/μL at Screening.
WEIGHT
• Body weight >=50 kg to <=115 kg.
INFORMED CONSENT • Participant is capable of giving written informed consent, which includes adherence to the requirements and restrictions listed in the consent form and in the protocol.
Exclusion Criteria:
CONCURRENT MEDICAL CONDITIONS & MEDICAL HISTORY
- Participant is pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study.
- Participant has documented diagnosis of HIV-2 infection.
- Participant is known to have acquired HIV via perinatal transmission.
- Any evidence of a current or known past Center for Disease Control and Prevention (CDC) Stage 3 disease.
- Any ongoing malignancy or history of systemic cancers, such as Kaposi's sarcoma and lymphoma, or other virus-associated malignancies.
- Ongoing or clinically relevant pancreatitis.
- Current HIV-related kidney disease.
- History of or active HIV-associated dementia or progressive multifocal leukoencephalopathy.
CARDIAC & CARDIOVASCULAR CONDITIONS
- Participants who are at clinically significant risk of cardiovascular disease.
- Ongoing or any lifetime history of clinically significant cardiovascular or cardiac disease.
- Confirmed QTcF value outside normal range at Screening or Day 1.
HEPATIC CONDITIONS
- History of clinically relevant hepatitis in the 6 months prior to Screening.
- Participants with severe hepatic impairment.
- Advanced MAFLD and advanced non-alcoholic steatohepatitis, if evidence for substantial fibrosis (fibrosis score ≥F2) or evidence of cirrhosis.
- Unstable liver disease.
- History of liver cirrhosis with or without hepatitis viral co-infection.
NEUROPSYCHIATRIC CONDITIONS • Participants who pose a significant suicide risk.
LABORATORY DIAGNOSTIC ASSESSMENTS
- Participants who are experiencing (Population 1) or are known to have initiated ART during (Population 2) acute HIV infection.
- Any verified Grade 4 laboratory abnormality at Screening, excluding asymptomatic elevations of lipids or CPK.
- Alanine transferase (ALT) >=3 times the upper limit of normal (ULN) at Screening.
- Estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m^2.
- Hemoglobin >=Grade 2 at Screening.
- Platelets >=Grade 2 at Screening.
- Absolute Neutrophil Count (ANC) ≥Grade 2 at Screening.
- Any acute abnormality at Screening, which, in the opinion of the investigator, would preclude the participant's inclusion in an interventional clinical study.
Population 2 only:
• Two or more plasma HIV-1 RNA results >=50 c/mL in the 18 months prior to Screening.
INFECTIOUS DISEASES
- Active hepatitis B virus (HBV) co-infection.
- Active hepatitis C virus (HCV) co-infection.
- Participant has untreated syphilis before enrolment.
- Known history of active Mycobacterium TB disease (regardless of treatment status).
ANTIRETROVIRAL RESISTANCE • Known major resistance-associated mutations to second-generation INSTIs or to antiretroviral (ARV) agents from 2 or more drug classes.
PRIOR AND CONCOMITANT MEDICATIONS
-
Prior use of any of the following agents:
- long-acting ARVs (any dose in the past 24 months or within 5 half-lives [whichever is longer])
- FTR (any lifetime use)
- HIV-1 immunotherapeutic vaccines or prophylactic vaccines (any lifetime use)
- HIV-1 monoclonal antibody therapy (any lifetime use).
-
Prior receipt of any approved or experimental non-HIV vaccination within 2 weeks prior to study enrolment.
-
History of systemic corticosteroids, immunosuppressive anti-cancer, interleukins, systemic interferons, or systemic chemotherapy, within 6 months prior to Screening.
-
Participant has received an experimental drug or experimental vaccine within either 30 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent (whichever is longer), prior to enrolment.
-
Treatment with any of the following agents within 30 days of enrolment:
- radiation therapy
- cytotoxic chemotherapeutic agents
- anti-tuberculosis therapy
- immunomodulators that alter immune responses such as chronic systemic corticosteroids, interleukins, or interferons.
-
Participant is receiving any protocol-defined prohibited medication and is unwilling or unable to switch to an alternate medication. Prohibited medications must be stopped within 7 days (or 14 days if the drug is a potential CYP3A4 enzyme inducer) or 5 half-lives (whichever is longer), prior to enrolment.
Population 1 only:
• Known use of PrEP or PEP within <30 days (for oral agents) or <52 weeks (for LA parenteral agents) of HIV-1 diagnosis. Participants with a documented seronegative result >=30 days after the last dose of oral PrEP or PEP (or >=52 weeks after the last dose of LA PrEP) are not excluded.
Population 2 only:
• Current use of NNRTI-containing ART.
OTHER EXCLUSIONS
- History or presence of allergy or intolerance to the study drugs or their components or drugs of their class, or a history of drug or other allergy that contraindicates study participation.
- Any condition which may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to receive study drugs.
- Any pre-existing physical or mental condition (including substance use disorder) which, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
- Participant is currently participating in, or anticipates being selected for, any other interventional study.
- Participant is known or suspected to be an HIV long-term non-progressor or elite controller, based on historical off-treatment plasma HIV-1 RNA results.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Aktiv komparator: Participants receiving SOC INSTI-based ART in Randomized Intervention Phase (Step 1)
|
A SOC INSTI-based ART regimen will be administered. |
|
Eksperimentell: Participants receiving SOC INSTI-based ART+VH3810109 in Randomized Intervention Phase (Step 1)
|
A SOC INSTI-based ART regimen will be administered. VH3810109 will be administered.
Andre navn:
|
|
Eksperimentell: Participants receiving SOC INSTI-based ART+VH3810109+FTR in Randomized Intervention Phase (Step 1)
|
A SOC INSTI-based ART regimen will be administered. VH3810109 will be administered.
Andre navn:
Fostemsavir will be administered.
Andre navn:
|
|
Eksperimentell: Participants receiving VH3810109 in ATI Phase (Step 2)
|
VH3810109 will be administered.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Randomized Intervention Phase (Step 1): Change from baseline in cell-associated HIV-1 RNA transcripts per million cluster of differentiation 4 (CD4+) T cells
Tidsramme: From Baseline (Day 1) to Month 12
|
From Baseline (Day 1) to Month 12
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Randomized Intervention Phase (Step 1): Change from baseline in total, intact, and defective proviral HIV-1 DNA per million CD4+ T cells
Tidsramme: From Baseline (Day 1) to Month 12
|
From Baseline (Day 1) to Month 12
|
|
Randomized Intervention Phase (Step 1): Absolute change in cell-associated HIV-1 RNA/proviral DNA ratios in CD4+ T cells
Tidsramme: From Baseline (Day 1) to Month 12
|
From Baseline (Day 1) to Month 12
|
|
Randomized Intervention Phase (Step 1): Absolute values for HIV-1-specific CD8+ T cell count
Tidsramme: From Baseline (Day 1) to Month 12
|
From Baseline (Day 1) to Month 12
|
|
Randomized Intervention Phase (Step 1): Change from baseline in HIV-1-specific CD8+ T cell count
Tidsramme: From Baseline (Day 1) to Month 12
|
From Baseline (Day 1) to Month 12
|
|
Randomized Intervention Phase (Step 1): Number of participants with Grade 3 and Grade 4 adverse events (AEs)
Tidsramme: From Baseline (Day 1) to Month 15
|
From Baseline (Day 1) to Month 15
|
|
Randomized Intervention Phase (Step 1): Number of participants with serious adverse events (SAEs), deaths and AEs leading to discontinuation of study intervention
Tidsramme: From Baseline (Day 1) to Month 15
|
From Baseline (Day 1) to Month 15
|
|
ATI Phase (Step 2): Time to ART restart
Tidsramme: From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
|
ATI Phase (Step 2): Number of participants with Grade 3 and Grade 4 AEs
Tidsramme: From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
|
ATI Phase (Step 2): Number of participants with SAEs and deaths
Tidsramme: From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
|
ATI Phase (Step 2): Number of participants with disease progression (HIV-associated conditions, acquired immunodeficiency syndrome [AIDS] and death)
Tidsramme: From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Blodbårne infeksjoner
- Urogenitale sykdommer
- Kjønnssykdommer
- Sykdommer i immunsystemet
- Infeksjoner
- RNA-virusinfeksjoner
- Virussykdommer
- Smittsomme sykdommer
- Seksuelt overførbare sykdommer, virale
- Seksuelt overførbare sykdommer
- Lentivirus infeksjoner
- Retroviridae-infeksjoner
- Immunologiske mangelsyndromer
- Langsomme virussykdommer
- HIV-infeksjoner
- Ervervet immunsviktsyndrom
- Fostemsavir
Andre studie-ID-numre
Andre studie-ID-numre
- 221794
- 2025-520629-19-00 (Annen identifikator: EU CT Number)
- 2025 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf
IPD-delingstidsramme
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
Tilgangskriterier for IPD-deling
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .